On March 17, 2016, a disclosure statement with respect to a plan of reorganization or liquidation was filed in the bankruptcy case of Neogenix Oncology, Inc. and its affiliates.
The filing was assigned docket number 572 and is described on the court’s official docket as follows:
Second Amended Disclosure Statement Filed by Neogenix Oncology, Inc.. (McKee, Thomas)
Neogenix Oncology, Inc. filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on July 23, 2012. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Maryland. The case number for the lead bankruptcy case is 12-23557. The bankruptcy case is currently assigned to United States Bankruptcy Judge Thomas Catliota. The law firm of Greenberg Traurig, LLP is acting as lead bankruptcy counsel to Neogenix Oncology, Inc. in the bankruptcy case.